文献速递乳腺癌放疗胸部肿瘤放疗

转化生长因子β1水平预测乳腺癌辅助放疗后三年超声心动图改变

Transforming growth factor beta 1 levels predict echocardiographic changes at three years after adjuvant radiotherapy for breast cancer.
PubMed 文献 · Radiat Oncol · 2019-08-30

该研究纳入63例接受辅助放疗的早期乳腺癌或导管原位癌女性,检测放疗前、放疗后及3年随访时血清TGF-β1和PDGF水平并行超声心动图检查。结果显示放疗前TGF-β1水平及3年TGF-β1变化与3年时整体纵向应变(GLS)相关,TGF-β1轨迹组1、左侧乳腺癌和芳香化酶抑制剂使用与GLS从放疗前至3年的恶化显著相关。结论提示放疗前TGF-β1升高可能预测放疗相关超声心动图改变。

要点

  • 放疗前TGF-β1水平与3年时GLS相关(Spearman rho 0.441,p<0.001)。
  • TGF-β1轨迹组1、左侧乳腺癌和芳香化酶抑制剂使用与GLS恶化独立相关。
  • PDGF在放疗后下降但3年时未持续,未显示与GLS的显著关联。

核心结论

  • 放疗前TGF-β1升高可能预测乳腺癌辅助放疗相关的超声心动图改变。

研究设计与样本

  • 研究纳入63例接受辅助放疗的早期乳腺癌或导管原位癌女性,放疗前、放疗后及3年随访时检测血清TGF-β1和PDGF并行超声心动图,采用轨迹分析对生物标志物分组。

主要发现

  • TGF-β1从放疗前19.2(IQR 17.1-22.3)降至放疗后18.8(14.5-22.0),p=0.003,3年时为17.2(13.7-21.2),p=0.101。
  • PDGF从放疗前15.4(12.6-19.1)降至放疗后13.8(11.7-16.2),p=0.001,3年时为15.6(10.4-18.4),p=0.661。
  • 放疗前TGF-β1水平(Spearman rho 0.441,p<0.001)及3年TGF-β1变化(rho=-0.302,p=0.018)与3年时GLS相关。
  • 轨迹分析发现两组TGF-β1行为,组1放疗前TGF-β1为25.6(22.3-28.6),显著高于组2的17.8(15.9-19.9),p<0.001。
  • 多变量分析中,TGF-β1轨迹组1(β=0.27,p=0.013)、左侧乳腺癌(β=0.39,p=0.001)和芳香化酶抑制剂使用(β=0.29,p=0.011)与GLS从放疗前至3年恶化显著相关。

临床怎么用

  • 对于接受辅助放疗的早期乳腺癌患者,可考虑检测放疗前血清TGF-β1以辅助识别放疗相关心脏超声改变高风险者。
  • 左侧乳腺癌及使用芳香化酶抑制剂的患者在接受辅助放疗时需关注心脏超声随访。

局限性

  • 研究样本量较小(63例),结果需更大样本验证。
  • TGF-β1从放疗后至3年的下降未达统计学显著(p=0.101)。
  • PDGF在3年时较放疗前的变化无统计学意义(p=0.661)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transforming growth factor beta 1 (TGF-β1) and platelet-derived growth factor (PDGF) are cytokines involved in fibrotic processes causing radiotherapy (RT)-induced cardiovascular changes. We aimed to investigate the associations between TGF-β1 and PDGF and the echocardiographic changes that occur during RT and during three-year follow-up. METHODS: The study included 63 women receiving adjuvant RT for early-stage breast cancer or ductal carcinoma in situ. Serum TGF-β1 (ng/ml) and PDGF (ng/ml) levels were measured by enzyme-linked immunoassay and echocardiographic examination was performed before RT, after RT and at 3 years. Patients were grouped by biomarker behavior by a trajectory analysis. RESULTS: TGF-β1 decreased from 19.2 (IQR 17.1-22.3) before RT to 18.8 (14.5-22.0) after RT (p = 0.003) and the decrease persisted at 17.2 (13.7-21.2) 3 years after RT (p = 0.101). PDGF decreased from 15.4 (12.6-19.1) before RT to 13.8 (11.7-16.2) after RT, p = 0.001, and persisted at 15.6 (10.4-18.4) at 3 years, p = 0.661. The TGF-β1 level before RT (Spearman's rho 0.441, p < 0.001) and the three-year change in TGF-β1 (rho = - 0.302, p = 0.018) correlated with global longitudinal strain (GLS) in echocardiography at 3 years. In trajectory analysis, two TGF-β1 behavior groups were found. Group 1 had significantly higher TGF-β1 levels before RT, 25.6 (22.3-28.6), than group 2, 17.8 (15.9-19.9), p < 0.001. In multivariable analysis, TGF-β1 trajectory group 1 (β = 0.27, p = 0.013), left-sided breast cancer (β = 0.39, p = 0.001) and the use of aromatase inhibitors (β = 0.29, p = 0.011) were significantly associated with a worsening in GLS from before RT to 3 years. CONCLUSION: An elevated pretreatment TGF-β1 may predict RT-associated changes in echocardiography.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Aula H, Skyttä T, Tuohinen S, et al. Transforming growth factor beta 1 levels predict echocardiographic changes at three years after adjuvant radiotherapy for breast cancer. Radiat Oncol. 2019. PMID: 31470867. doi:10.1186/s13014-019-1366-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。